Moreover, therapies designed to target ER are expected to be most effective for ER+/GPER− cancers, whereas for ER+/GPER+ cancers, efficacy will always be limited by the extent of undrugged GPER involvement, or where such therapies adventitiously target GPER. This evidence concerns the gene ESR1 and cancer.